Literature DB >> 33592621

Performance Comparison of GeneXpert MTB/RIF and ProbeTec ET Tests for Rapid Molecular Diagnosis of Extrapulmonary Tuberculosis in a Low TB/MDR-TB Incidence Country.

Eiman Mokaddas1,2, Suhail Ahmad1, Hanaa Eldeen2.   

Abstract

OBJECTIVE: This study evaluated the performance of GeneXpert MTB/RIF (Xpert) and ProbeTec ET (PTec-ET) assays in diagnosing extrapulmonary tuberculosis (EPTB) in Kuwait.
MATERIALS AND METHODS: We tested nonrespiratory clinical specimens (n = 3,995) collected from 3,995 patients suspected to have EPTB. These included cavitary fluids (n = 2,054), fine-needle aspirate (FNA)/pus/tissue biopsy (n = 1,461), urine (n = 302), cerebrospinal fluid (CSF, n = 118), and others (n = 60). All specimens were processed for acid-fast bacilli (AFB), culture in mycobacteria growth indicator tube 960 system, and nucleic acid detection by Xpert and PTec-ET according to manufacturer's instructions.
RESULTS: Of 3,995 specimens, 95 were AFB-positive, 403 were culture-positive, and an additional 86 samples had histopathology suggestive of TB. Using culture as reference, the sensitivity and specificity values were 88.33 and 97.3% for Xpert and 72.95 and 97.80% for PTec-ET, respectively. Although performance of both tests was comparable in AFB-positive samples, Xpert detected significantly more cases in culture-positive samples. Among culture-negative samples, Xpert detected 18 more cases including 16 with histopathological evidence of TB. Lowest positivity was detected for both tests in cavitary fluids. Xpert performed better than PTec-ET in culture-positive FNA/pus/tissue biopsy and CSF samples.
CONCLUSIONS: Although performance of both tests was suboptimal for AFB-negative/culture-positive samples, Xpert performed better than PTec-ET and also detected more cases of AFB-negative/culture-negative/histopathology-positive samples. PTec-ET was positive in 3, while Xpert was positive in all 6 culture-positive CSF specimens for rapid diagnosis of TB meningitis. Xpert was thus superior to PTec-ET or smear microscopy in rapid diagnosis of EPTB.
© 2021 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Extrapulmonary tuberculosis; Kuwait; Molecular diagnosis; Mycobacterium tuberculosis; Probe Tec ET test; Xpert MTB/RIF assay

Mesh:

Year:  2021        PMID: 33592621      PMCID: PMC8280443          DOI: 10.1159/000515254

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


  29 in total

1.  Potential of two nucleic acid amplification assays for quantifying mycobacterial load in respiratory and non-respiratory specimens: a prospective study.

Authors:  Amani Mansour Alnimr; Manal Ismail Hassan
Journal:  Diagn Microbiol Infect Dis       Date:  2013-11-27       Impact factor: 2.803

2.  Diversity of Nontuberculous Mycobacteria in Kuwait: Rapid Identification and Differentiation of Mycobacterium Species by Multiplex PCR, INNO-LiPA Mycobacteria v2 Assay and PCR Sequencing of rDNA.

Authors:  Suhail Ahmad; Eiman Mokaddas
Journal:  Med Princ Pract       Date:  2019-02-14       Impact factor: 1.927

Review 3.  The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.

Authors:  Keertan Dheda; Tawanda Gumbo; Gary Maartens; Kelly E Dooley; Ruth McNerney; Megan Murray; Jennifer Furin; Edward A Nardell; Leslie London; Erica Lessem; Grant Theron; Paul van Helden; Stefan Niemann; Matthias Merker; David Dowdy; Annelies Van Rie; Gilman K H Siu; Jotam G Pasipanodya; Camilla Rodrigues; Taane G Clark; Frik A Sirgel; Aliasgar Esmail; Hsien-Ho Lin; Sachin R Atre; H Simon Schaaf; Kwok Chiu Chang; Christoph Lange; Payam Nahid; Zarir F Udwadia; C Robert Horsburgh; Gavin J Churchyard; Dick Menzies; Anneke C Hesseling; Eric Nuermberger; Helen McIlleron; Kevin P Fennelly; Eric Goemaere; Ernesto Jaramillo; Marcus Low; Carolina Morán Jara; Nesri Padayatchi; Robin M Warren
Journal:  Lancet Respir Med       Date:  2017-03-15       Impact factor: 30.700

4.  Evaluation of the BD MAX™ MDR-TB assay in a real-world setting for the diagnosis of pulmonary and extra-pulmonary TB.

Authors:  H Ciesielczuk; N Kouvas; N North; R Buchanan; S Tiberi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-02-20       Impact factor: 3.267

Review 5.  Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis.

Authors:  Suhail Ahmad; Eiman Mokaddas
Journal:  J Infect Public Health       Date:  2013-11-09       Impact factor: 3.718

6.  Secular trends in susceptibility patterns of Mycobacterium tuberculosis isolates in Kuwait, 1996-2005.

Authors:  E Mokaddas; S Ahmad; I Samir
Journal:  Int J Tuberc Lung Dis       Date:  2008-03       Impact factor: 2.373

Review 7.  The development, evaluation and performance of molecular diagnostics for detection of Mycobacterium tuberculosis.

Authors:  Matthew Bates; Alimuddin Zumla
Journal:  Expert Rev Mol Diagn       Date:  2016-02-17       Impact factor: 5.225

Review 8.  Tuberculosis: advances and challenges in development of new diagnostics and biomarkers.

Authors:  Gerhard Walzl; Ruth McNerney; Nelita du Plessis; Matthew Bates; Timothy D McHugh; Novel N Chegou; Alimuddin Zumla
Journal:  Lancet Infect Dis       Date:  2018-03-23       Impact factor: 25.071

Review 9.  Diagnostic accuracy of the Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis when testing non-respiratory samples: a systematic review.

Authors:  Laura Maynard-Smith; Natasha Larke; Jurgens A Peters; Stephen D Lawn
Journal:  BMC Infect Dis       Date:  2014-12-31       Impact factor: 3.090

10.  Evaluation of pulmonary and extrapulmonary tuberculosis in immunocompetent adults: a retrospective case series analysis.

Authors:  Selma Ates Guler; Fulsen Bozkus; Mehmet Fatih Inci; Omer Faruk Kokoglu; Hasan Ucmak; Sevinc Ozden; Murvet Yuksel
Journal:  Med Princ Pract       Date:  2014-10-17       Impact factor: 1.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.